Malignant tumor of nasopharynx
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- A cancer that involves the nasopharynx.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Malignant tumor of nasopharynx
- Therapeutic area
- Gastroenterology
- malignant tumor of nasopharynx
- cancer of nasopharynx
- malignant nasopharyngeal neoplasm
- malignant nasopharyngeal tumor
- malignant nasopharyngeal tumour
- malignant nasopharynx neoplasm
- malignant neoplasm of nasopharynx
- malignant neoplasm of the nasopharynx
- malignant tumor of the nasopharynx
- malignant tumour of the nasopharynx
- nasopharynx cancer
- Severity
- Severe
- Gastroenterology
- Oncology
- Pulmonology
Sources for recorded values
- MONDO ID
- MONDO:0021315
- Parent condition
- MONDO:0005375
Related records
Broader conditions (25)
- Cancer
- Cancer or benign tumor
- Digestive system cancer
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disorder of pharynx
- Head and neck cancer
- Head and neck neoplasm
- Human disease
- Malignant tumor of neck
- Nasopharyngeal disorder
- Nasopharyngeal neoplasm
- Neoplasm
- Neoplasm of neck
- Neoplastic disease or syndrome
- Otorhinolaryngologic disease
- Pharynx cancer
Narrower conditions (3)
- Carcinoma in situ of nasopharynx
- Nasopharyngeal carcinoma
- Undifferentiated carcinoma of nasopharynx
Trials (82)
- 124I-FIAU Imaging in EBV and KSHV Associated Cancers
- 3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma
- 68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
- A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients
- A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
- A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors
- A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
- A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer
- A Study of Nasopharyngeal Carcinoma From Guangdong
- A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
- A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
- A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
- Acupuncture for Prevention of Radiation-Induced Xerostomia
- Adaptive Radiotherapy for Head and Neck Cancer
- Adebrelimab and Chemoradiotherapy in High-risk LANPC
- Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer
- An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Drugs in development (5)
- Carboplatin Phase 3
- Cisplatin Phase 3
- Endostatin Phase 2
- Fluorouracil Phase 3
- Gemcitabine Phase 2